Emerging Therapies in the Preventive Care of Migraine

Welcome to the registration website for
Emerging Therapies in the Preventive Care of Migraine!

Join us for this breakfast symposium at the Update in Headache Meeting and earn 1.0 credit hour of continuing education. The meeting includes complimentary breakfast.



Saturday, November 18, 2017
6:45 am - 7:45 am

The Westin Michigan Avenue
Great Lakes Grand Ballroom
909 North Michigan Avenue
Chicago, Illinois 60611

PROGRAM OVERVIEW
Join the discussion with our faculty as they present the most up-to-date information being reported in clinical trials for the new calcitonin gene-related peptide (CGRP) inhibitors. Whether you’re learning this information for the first time or you want to hear more of the latest information about the promise of new therapies on the horizon for preventive treatment of chronic and episodic migraine, you’ll leave this session with a new insight into how what’s happening in clinical trials today will impact your practice in the near future.

TARGET AUDIENCE
This activity is designed for clinicians who have an interest in migraine and other headache disorders in attendance at the Update in Headache 2017 Meeting.

LEARNING OBJECTIVES
Upon completion of this educational activity, participants should be able to:
  • Outline current challenges and barriers to the effective prevention of migraine
  • Describe the role of calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine
  • Identify emerging treatments with novel mechanisms of action
  • Summarize data focusing on new and emerging preventive treatments for episodic and chronic migraine
FACULTY
Merle L. Diamond, MD Merle L. Diamond, MD - Chair
President, Managing Director
Diamond Headache Clinic
Chicago, Illinois
Robert G. Kaniecki, MD Robert G. Kaniecki, MD
Director, the Headache Center
Chief, Headache Division
Assistant Director, Neurology Residency Training Program
Director, Headache Fellowship Program
Assistant Professor of Neurology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

AGENDA
Breakfast will be provided.

6:45 am – 6:50 am Moderator's Welcome and Activity Overview
6:50 am – 7:05 am The Migraine Evolution Process and Treatment Today
  • Only one-third of people with migraine who meet guidelines for preventive treatments receive them; how does this compare to your practice?
  • A closer look at preventive treatment: an area of substantial unmet need and how we can optimize the appropriate use of preventive treatments
7:05 am – 7:35 am Moving From Bench to Practice: Expert Perspectives on the Future of Prevention in Migraine
  • A look at the unique features of CGRP mAbs while examining new data across current clinical trials
7:35 am – 7:45 am Audience Feedback/Panel Discussion
  • What are your challenges in the treatment of migraine?

ACCREDITATION  
MediCom Worldwide, Inc. CME Credit
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-17-177-L01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
MediCom Worldwide, Inc. Nursing Credit
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 17-177-068

DISCLOSURE
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

AMERICANS WITH DISABILITIES ACT/SPECIAL NEEDS
MediCom Worldwide, Inc. is committed to equality of educational opportunity and does not discriminate against applicants, students, or employees on the basis of race, color, religion, sex, national origin, age, disability, veterans status, or sexual orientation. If you require reasonable accommodations for a disability in order to participate fully in this continuing education activity, please call 800-408-4242 no later than 14 days prior to the activity.

INSTRUCTIONS FOR PARTICIPATION AND CREDIT
There are no fees for participating in this activity. In order to receive credit, all participants must complete the Activity Evaluation Form following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment portion of the form to qualify for CE credit. CME/CNE certificates will be e-mailed 4 weeks following receipt of a completed, qualified form. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, ext. 128 or email lisa@medicaled.com

MediCom Worldwide, Inc. Provided by
MediCom Worldwide, Inc.

Supported by an educational grant from Teva Pharmaceuticals